Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

STING data from Spring Bank
November 2017
SHARING OPTIONS:

HOPKINTON, Mass.—This year at the AACR Conference on Tumor Immunology and Immunotherapy, Spring Bank Pharmaceuticals Inc. shared data from its preclinical studies of SB11285, a next-generation, proprietary STING agonist compound. The poster presented, “Pharmacodynamic and preclinical studies of SB 11285, a highly potent, and systemically bioavailable STING agonist as a novel immunotherapeutic agent,” highlighted data from studies in multiple syngeneic mouse models—including A20 lymphoma, CT26 colon carcinoma, B16 melanoma and orthotopic 4T1 breast cancer models—looking at SB 11285’s capacity for tumor growth inhibition and tumor growth delay.
 
“Data from multiple tumor models in preclinical studies of SB 11285 demonstrated durable antitumor activity and support continued development of SB 11285, either alone or in combination with other agents, with different routes of administration,” said Dr. Radhakrishnan (Kris) Iyer, Spring Bank’s chief scientific officer. “We are conducting additional preclinical and IND-enabling studies to support the initiation of the SB 11285 clinical program in mid-2018.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.